261 related articles for article (PubMed ID: 16315032)
1. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
Nieminen T; Lehtimäki T; Mäenpää J; Ropo A; Uusitalo H; Kähönen M
Scand J Clin Lab Invest; 2007; 67(2):237-45. PubMed ID: 17366003
[TBL] [Abstract][Full Text] [Related]
3. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle Glaucoma--a pilot study.
Yuan H; Yu M; Yang Y; Wu K; Lin X; Li J
J Ocul Pharmacol Ther; 2010 Oct; 26(5):497-501. PubMed ID: 20925579
[TBL] [Abstract][Full Text] [Related]
5. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
[TBL] [Abstract][Full Text] [Related]
9. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients.
Nieminen T; Uusitalo H; Turjanmaa V; Bjärnhall G; Hedenström H; Mäenpää J; Ropo A; Heikkilä P; Kähönen M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):369-74. PubMed ID: 15912390
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
11. Multiplex SNaPshot-a new simple and efficient CYP2D6 and ADRB1 genotyping method.
Ben S; Cooper-DeHoff RM; Flaten HK; Evero O; Ferrara TM; Spritz RA; Monte AA
Hum Genomics; 2016 Apr; 10():11. PubMed ID: 27108086
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
Edeki TI; He H; Wood AJ
JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol.
Yang Y; Wu K; Yuan H; Yu M
J Ocul Pharmacol Ther; 2009 Apr; 25(2):163-71. PubMed ID: 19284319
[TBL] [Abstract][Full Text] [Related]
15. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
Korte JM; Kaila T; Saari KM
Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
[TBL] [Abstract][Full Text] [Related]
17. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
18. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
19. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects.
Ferro A; Hall JA; Dickerson JE; Brown MJ
Br J Clin Pharmacol; 1997 Mar; 43(3):301-8. PubMed ID: 9088585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
